RxDoctor Payments Data

Madonna Loudermilk, APRN

Family · Pine Knot, KYNPI 1063948594

Payments from drug & device makers

$1,065in general payments, 2019–2025

Across 66 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$187
  • Lilly USA, LLC$176
  • AstraZeneca$159
  • Novo Nordisk$99
  • Boehringer Ingelheim$69
  • Novartis$67
  • plus $308 from 10 others

What the payments were for

  • Food & beverage$1,065100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,065 in reported general payments places this provider in the 65th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,156
Medicare patients
64
Services billed
237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide117$127,326
OzempicSemaglutide72$68,545
Xeljanz XrTofacitinib Citrate11$62,602
EliquisApixaban42$45,175
JardianceEmpagliflozin38$44,738
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$30,036
TrulicityDulaglutide26$25,257
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$16,488
VraylarCariprazine Hcl14$16,351
SynjardyEmpagliflozin/Metformin Hcl22$14,572
XareltoRivaroxaban21$13,942
Tresiba Flextouch U-200Insulin Degludec14$13,057
Tresiba Flextouch U-100Insulin Degludec19$12,664
TradjentaLinagliptin23$11,758
Breo ElliptaFluticasone/Vilanterol17$10,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$176$152,583143 claims
Boehringer IngelheimJardiance, Synjardy, Tradjenta$69$71,06783 claims
Novo NordiskOzempic$99$68,54572 claims
PfizerEliquis$15$45,17542 claims
GSKTrelegy Ellipta, Breo Ellipta$45$40,78354 claims
AstraZenecaBreztri Aerosphere, Symbicort$159$20,52332 claims
AbbVieVraylar, Synthroid$61$17,83848 claims
MerckJanumet$24$9,56611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,374 family providers in Kentucky.

Other family in Pine Knot

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →